Company profile
Biostax Corp.
OTC: BTAX · Healthcare · Biotechnology
#1043 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 20GM —SS 30
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), listing tenure · ↓ balance-sheet leverage, workforce scale
Methodology →Revenue TTM
$113.5k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.7M
Employees
4
as of 2026-08-03
Market cap
$7.9k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$113.5k$113.5k2018
Net income-$1.7M-$1.7M2023
Operating income-$1.5M-$1.5M2023
Total assets$743.5k$743.5k2023
Liabilities$4.6M$4.6M2023
Equity-$3.8M-$3.8M2023
Revenue trend
FY2014 – FY2018 · USD
FY14
FY14
FY15
FY16
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Biostax Corp.’s revenue?
Biostax Corp. booked $113.5k in FY2018 revenue, growing 3178% year over year — faster than 98% of Healthcare companies we track, at a -1454.2% net margin.
Peers · Healthcare
Bullfrog AI Holdings, Inc. Common Stock30DCreative Edge Nutrition, Inc.——Forza Innovations Inc.——BioMark Diagnostics Inc.——Finch Therapeutics Group, Inc.——Meridian Holdings, Inc.——Neighbors
Orange →Key facts
CEONoreen Griffin
SectorHealthcare
IndustryBiotechnology
HeadquartersWinter Park, FL
ExchangeOTC: BTAX
Employees4
IPO date2010-08-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.